{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T09:13:09Z","timestamp":1789809189022,"version":"4.0.1"},"reference-count":152,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,1,18]],"date-time":"2016-01-18T00:00:00Z","timestamp":1453075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,1,18]],"date-time":"2016-01-18T00:00:00Z","timestamp":1453075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1038\/nrneurol.2015.248","type":"journal-article","created":{"date-parts":[[2016,1,19]],"date-time":"2016-01-19T06:48:06Z","timestamp":1453186086000},"page":"95-105","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":130,"title":["CCR5 blockade for neuroinflammatory diseases \u2014 beyond control of HIV"],"prefix":"10.1038","volume":"12","author":[{"given":"Guillaume","family":"Martin-Blondel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Brassat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Lassmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland S.","family":"Liblau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,18]]},"reference":[{"key":"BFnrneurol2015248_CR1","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1146\/annurev-immunol-032713-120145","volume":"32","author":"JW Griffith","year":"2014","unstructured":"Griffith, J. W., Sokol, C. L. & Luster, A. D. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu. Rev. Immunol. 32, 659\u2013702 (2014).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnrneurol2015248_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-62703-426-5_1","volume":"1013","author":"SM Cardona","year":"2013","unstructured":"Cardona, S. M., Garcia, J. A. & Cardona, A. E. The fine balance of chemokines during disease: trafficking, inflammation, and homeostasis. Methods Mol. Biol. 1013, 1\u201316 (2013).","journal-title":"Methods Mol. Biol."},{"key":"BFnrneurol2015248_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.coviro.2012.12.002","volume":"3","author":"TJ Henrich","year":"2013","unstructured":"Henrich, T. J. & Kuritzkes, D. R. HIV-1 entry inhibitors: recent development and clinical use. Curr. Opin. Virol. 3, 51\u201357 (2013).","journal-title":"Curr. Opin. Virol."},{"key":"BFnrneurol2015248_CR4","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/84205","volume":"2","author":"SA Luther","year":"2001","unstructured":"Luther, S. A. & Cyster, J. G. Chemokines as regulators of T cell differentiation. Nat. Immunol. 2, 102\u2013107 (2001).","journal-title":"Nat. Immunol."},{"key":"BFnrneurol2015248_CR5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0952-7915(01)00308-9","volume":"14","author":"AD Luster","year":"2002","unstructured":"Luster, A. D. The role of chemokines in linking innate and adaptive immunity. Curr. Opin. Immunol. 14, 129\u2013135 (2002).","journal-title":"Curr. Opin. Immunol."},{"key":"BFnrneurol2015248_CR6","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.4049\/jimmunol.161.7.3330","volume":"161","author":"M Nieto","year":"1998","unstructured":"Nieto, M. et al. Roles of chemokines and receptor polarization in NK-target cell interactions. J. Immunol. 161, 3330\u20133339 (1998).","journal-title":"J. Immunol."},{"key":"BFnrneurol2015248_CR7","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1016\/j.yexcr.2009.06.017","volume":"315","author":"MH Park","year":"2009","unstructured":"Park, M. H. et al. Chemokines released from astrocytes promote chemokine receptor 5-mediated neuronal cell differentiation. Exp. Cell Res. 315, 2715\u20132726 (2009).","journal-title":"Exp. Cell Res."},{"key":"BFnrneurol2015248_CR8","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/jnen\/59.5.339","volume":"59","author":"JA Shukaliak","year":"2000","unstructured":"Shukaliak, J. A. & Dorovini-Zis, K. Expression of the \u03b2-chemokines RANTES and MIP-1\u03b2 by human brain microvessel endothelial cells in primary culture. J. Neuropathol. Exp. Neurol. 59, 339\u2013352 (2000).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"BFnrneurol2015248_CR9","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/NEN.0b013e318197eca7","volume":"68","author":"EA Subileau","year":"2009","unstructured":"Subileau, E. A. et al. Expression of chemokines and their receptors by human brain endothelium: implications for multiple sclerosis. J. Neuropathol. Exp. Neurol. 68, 227\u2013240 (2009).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"BFnrneurol2015248_CR10","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.4049\/jimmunol.0901903","volume":"184","author":"AR Ferguson","year":"2010","unstructured":"Ferguson, A. R. & Engelhard, V. H. CD8 T cells activated in distinct lymphoid organs differentially express adhesion proteins and coexpress multiple chemokine receptors. J. Immunol. 184, 4079\u20134086 (2010).","journal-title":"J. Immunol."},{"key":"BFnrneurol2015248_CR11","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/nature04651","volume":"440","author":"F Castellino","year":"2006","unstructured":"Castellino, F. et al. Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature 440, 890\u2013895 (2006).","journal-title":"Nature"},{"key":"BFnrneurol2015248_CR12","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1084\/jem.20102545","volume":"208","author":"HD Hickman","year":"2011","unstructured":"Hickman, H. D. et al. Chemokines control naive CD8+ T cell selection of optimal lymph node antigen presenting cells. J. Exp. Med. 208, 2511\u20132524 (2011).","journal-title":"J. Exp. Med."},{"key":"BFnrneurol2015248_CR13","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/ni.1848","volume":"11","author":"V Semmling","year":"2010","unstructured":"Semmling, V. et al. Alternative cross-priming through CCL17\u2013CCR4-mediated attraction of CTLs toward NKT cell-licensed DCs. Nat. Immunol. 11, 313\u2013320 (2010).","journal-title":"Nat. Immunol."},{"key":"BFnrneurol2015248_CR14","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/ni1495","volume":"8","author":"S Hugues","year":"2007","unstructured":"Hugues, S. et al. Dynamic imaging of chemokine-dependent CD8+ T cell help for CD8+ T cell responses. Nat. Immunol. 8, 921\u2013930 (2007).","journal-title":"Nat. Immunol."},{"key":"BFnrneurol2015248_CR15","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/ni1191","volume":"6","author":"B Molon","year":"2005","unstructured":"Molon, B. et al. T cell costimulation by chemokine receptors. Nat. Immunol. 6, 465\u2013471 (2005).","journal-title":"Nat. Immunol."},{"key":"BFnrneurol2015248_CR16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.4049\/jimmunol.182.1.171","volume":"182","author":"JF Camargo","year":"2009","unstructured":"Camargo, J. F. et al. CCR5 expression levels influence NFAT translocation, IL-2 production, and subsequent signaling events during T lymphocyte activation. J. Immunol. 182, 171\u2013182 (2009).","journal-title":"J. Immunol."},{"key":"BFnrneurol2015248_CR17","doi-asserted-by":"publisher","first-page":"10101","DOI":"10.1073\/pnas.0804286105","volume":"105","author":"RL Contento","year":"2008","unstructured":"Contento, R. L. et al. CXCR4\u2013CCR5: a couple modulating T cell functions. Proc. Natl Acad. Sci. USA 105, 10101\u201310106 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2015248_CR18","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/ni.2029","volume":"12","author":"BS Sheridan","year":"2011","unstructured":"Sheridan, B. S. & Lefran\u00e7ois, L. Regional and mucosal memory T cells. Nat. Immunol. 12, 485\u2013491 (2011).","journal-title":"Nat. Immunol."},{"key":"BFnrneurol2015248_CR19","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1084\/jem.187.6.875","volume":"187","author":"F Sallusto","year":"1998","unstructured":"Sallusto, F., Lenig, D., Mackay, C. R. & Lanzavecchia, A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J. Exp. Med. 187, 875\u2013883 (1998).","journal-title":"J. Exp. Med."},{"key":"BFnrneurol2015248_CR20","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.4049\/jimmunol.168.5.2225","volume":"168","author":"K Fukada","year":"2002","unstructured":"Fukada, K., Sobao, Y., Tomiyama, H., Oka, S. & Takiguchi, M. Functional expression of the chemokine receptor CCR5 on virus epitope-specific memory and effector CD8+ T cells. J. Immunol. 168, 2225\u20132232 (2002).","journal-title":"J. Immunol."},{"key":"BFnrneurol2015248_CR21","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.immuni.2008.05.011","volume":"29","author":"JE Kohlmeier","year":"2008","unstructured":"Kohlmeier, J. E. et al. The chemokine receptor CCR5 plays a key role in the early memory CD8+ T cell response to respiratory virus infections. Immunity 29, 101\u2013113 (2008).","journal-title":"Immunity"},{"key":"BFnrneurol2015248_CR22","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nri3641","volume":"14","author":"W Weninger","year":"2014","unstructured":"Weninger, W., Biro, M. & Jain, R. Leukocyte migration in the interstitial space of non-lymphoid organs. Nat. Rev. Immunol. 14, 232\u2013246 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"BFnrneurol2015248_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.cellimm.2006.12.001","volume":"243","author":"EE Ubogu","year":"2006","unstructured":"Ubogu, E. E., Callahan, M. K., Tucky, B. H. & Ransohoff, R. M. CCR5 expression on monocytes and T cells: modulation by transmigration across the blood\u2013brain barrier in vitro. Cell. Immunol. 243, 19\u201329 (2006).","journal-title":"Cell. Immunol."},{"key":"BFnrneurol2015248_CR24","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1093\/jnen\/63.4.350","volume":"63","author":"J Quandt","year":"2004","unstructured":"Quandt, J. & Dorovini-Zis, K. The \u03b2 chemokines CCL4 and CCL5 enhance adhesion of specific CD4+ T cell subsets to human brain endothelial cells. J. Neuropathol. Exp. Neurol. 63, 350\u2013362 (2004).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"BFnrneurol2015248_CR25","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1084\/jem.20102110","volume":"208","author":"JE Kohlmeier","year":"2011","unstructured":"Kohlmeier, J. E. et al. Inflammatory chemokine receptors regulate CD8+ T cell contraction and memory generation following infection. J. Exp. Med. 208, 1621\u20131634 (2011).","journal-title":"J. Exp. Med."},{"key":"BFnrneurol2015248_CR26","doi-asserted-by":"publisher","first-page":"e92477","DOI":"10.1371\/journal.pone.0092477","volume":"9","author":"S Das","year":"2014","unstructured":"Das, S. et al. Immune subversion by Mycobacterium tuberculosis through CCR5 mediated signaling: involvement of IL-10. PLoS ONE 9, e92477 (2014).","journal-title":"PLoS ONE"},{"key":"BFnrneurol2015248_CR27","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.2337\/db11-1506","volume":"61","author":"H Kitade","year":"2012","unstructured":"Kitade, H. et al. CCR5 plays a critical role in obesity-induced adipose tissue inflammation and insulin resistance by regulating both macrophage recruitment and M1\/M2 status. Diabetes 61, 1680\u20131690 (2012).","journal-title":"Diabetes"},{"key":"BFnrneurol2015248_CR28","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/j.1365-2249.2011.04409.x","volume":"166","author":"R Rossi","year":"2011","unstructured":"Rossi, R. et al. In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells. Clin. Exp. Immunol. 166, 184\u2013190 (2011).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnrneurol2015248_CR29","doi-asserted-by":"publisher","first-page":"567","DOI":"10.4049\/jimmunol.1200266","volume":"189","author":"LY Chang","year":"2012","unstructured":"Chang, L. Y. et al. The indispensable role of CCR5 for in vivo suppressor function of tumor-derived CD103+ effector\/memory regulatory T cells. J. Immunol. 189, 567\u2013574 (2012).","journal-title":"J. Immunol."},{"key":"BFnrneurol2015248_CR30","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/ni1521","volume":"8","author":"MJ Dolan","year":"2007","unstructured":"Dolan, M. J. et al. CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nat. Immunol. 8, 1324\u20131336 (2007).","journal-title":"Nat. Immunol."},{"key":"BFnrneurol2015248_CR31","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.4049\/jimmunol.160.8.4018","volume":"160","author":"Y Zhou","year":"1998","unstructured":"Zhou, Y. et al. Impaired macrophage function and enhanced T cell-dependent immune response in mice lacking CCR5, the mouse homologue of the major HIV-1 coreceptor. J. Immunol. 160, 4018\u20134025 (1998).","journal-title":"J. Immunol."},{"key":"BFnrneurol2015248_CR32","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/381667a0","volume":"381","author":"T Dragic","year":"1996","unstructured":"Dragic, T. et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381, 667\u2013673 (1996).","journal-title":"Nature"},{"key":"BFnrneurol2015248_CR33","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/00042560-199909010-00010","volume":"22","author":"GT Nguy\u00ea\u00f1","year":"1999","unstructured":"Nguy\u00ea\u00f1, G. T. et al. Phenotypic expressions of CCR5-\u039432\/\u039432 homozygosity. J. Acquir. Immune Defic. Syndr. 22, 75\u201382 (1999).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"BFnrneurol2015248_CR34","first-page":"1341","volume":"151","author":"JB Rottman","year":"1997","unstructured":"Rottman, J. B. et al. Cellular localization of the chemokine receptor CCR5. Correlation to cellular targets of HIV-1 infection. Am. J. Pathol. 151, 1341\u20131351 (1997).","journal-title":"Am. J. Pathol."},{"key":"BFnrneurol2015248_CR35","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/S0165-5728(01)00457-X","volume":"122","author":"SV Westmoreland","year":"2002","unstructured":"Westmoreland, S. V. et al. Developmental expression patterns of CCR5 and CXCR4 in the rhesus macaque brain. J. Neuroimmunol. 122, 146\u2013158 (2002).","journal-title":"J. Neuroimmunol."},{"key":"BFnrneurol2015248_CR36","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.nbd.2012.08.001","volume":"49","author":"DY Choi","year":"2013","unstructured":"Choi, D. Y., Lee, M. K. & Hong, J. T. Lack of CCR5 modifies glial phenotypes and population of the nigral dopaminergic neurons, but not MPTP-induced dopaminergic neurodegeneration. Neurobiol. Dis. 49, 159\u2013168 (2013).","journal-title":"Neurobiol. Dis."},{"key":"BFnrneurol2015248_CR37","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.4049\/jimmunol.163.3.1636","volume":"163","author":"RS Klein","year":"1999","unstructured":"Klein, R. S. et al. Chemokine receptor expression and signaling in macaque and human fetal neurons and astrocytes: implications for the neuropathogenesis of AIDS. J. Immunol. 163, 1636\u20131646 (1999).","journal-title":"J. Immunol."},{"key":"BFnrneurol2015248_CR38","doi-asserted-by":"publisher","first-page":"14500","DOI":"10.1073\/pnas.95.24.14500","volume":"95","author":"O Meucci","year":"1998","unstructured":"Meucci, O. et al. Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. Proc. Natl Acad. Sci. USA 95, 14500\u201314505 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2015248_CR39","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/ng0597-100","volume":"16","author":"JJ Martinson","year":"1997","unstructured":"Martinson, J. J., Chapman, N. H., Rees, D. C., Liu, Y. T. & Clegg, J. B. Global distribution of the CCR5 gene 32-basepair deletion. Nat. Genet. 16, 100\u2013103 (1997).","journal-title":"Nat. Genet."},{"key":"BFnrneurol2015248_CR40","doi-asserted-by":"publisher","first-page":"e339","DOI":"10.1371\/journal.pbio.0030339","volume":"3","author":"J Novembre","year":"2005","unstructured":"Novembre, J., Galvani, A. P. & Slatkin, M. The geographic spread of the CCR5 \u039432 HIV-resistance allele. PLoS Biol. 3, e339 (2005).","journal-title":"PLoS Biol."},{"key":"BFnrneurol2015248_CR41","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1126\/science.273.5283.1856","volume":"273","author":"M Dean","year":"1996","unstructured":"Dean, M. et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 273, 1856\u20131862 (1996).","journal-title":"Science"},{"key":"BFnrneurol2015248_CR42","doi-asserted-by":"publisher","first-page":"782","DOI":"10.7326\/0003-4819-135-9-200111060-00008","volume":"135","author":"JP Ioannidis","year":"2001","unstructured":"Ioannidis, J. P. et al. Effects of CCR5-\u039432, CCR2-64I, and SDF-1 3\u2032A alleles on HIV-1 disease progression: an international meta-analysis of individual-patient data. Ann. Intern. Med. 135, 782\u2013795 (2001).","journal-title":"Ann. Intern. Med."},{"key":"BFnrneurol2015248_CR43","doi-asserted-by":"publisher","first-page":"5502","DOI":"10.1128\/JVI.00118-15","volume":"89","author":"WE Walker","year":"2015","unstructured":"Walker, W. E. et al. Increased levels of macrophage inflammatory proteins result in resistance to R5-tropic HIV-1 in a subset of elite controllers. J. Virol. 89, 5502\u20135514 (2015).","journal-title":"J. Virol."},{"key":"BFnrneurol2015248_CR44","doi-asserted-by":"publisher","first-page":"4584","DOI":"10.1128\/AAC.49.11.4584-4591.2005","volume":"49","author":"M Baba","year":"2005","unstructured":"Baba, M. et al. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans. Antimicrob. Agents Chemother. 49, 4584\u20134591 (2005).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrneurol2015248_CR45","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/QAI.0b013e3182a7a97a","volume":"65","author":"RM Gulick","year":"2014","unstructured":"Gulick, R. M. et al. Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patients. J. Acquir. Immune Defic. Syndr. 65, 78\u201381 (2014).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"BFnrneurol2015248_CR46","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1179\/1528433614Z.0000000002","volume":"16","author":"A Lazzarin","year":"2015","unstructured":"Lazzarin, A. et al. The maraviroc expanded access program \u2014 safety and efficacy data from an open-label study. HIV Clin. Trials 16, 10\u201321 (2015).","journal-title":"HIV Clin. Trials"},{"key":"BFnrneurol2015248_CR47","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.antiviral.2015.05.001","volume":"120","author":"JM Llibre","year":"2015","unstructured":"Llibre, J. M. et al. Safety, efficacy and indications of prescription of maraviroc in clinical practice: factors associated with clinical outcomes. Antiviral Res. 120, 79\u201384 (2015).","journal-title":"Antiviral Res."},{"key":"BFnrneurol2015248_CR48","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/nm1319","volume":"11","author":"G F\u00e4tkenheuer","year":"2005","unstructured":"F\u00e4tkenheuer, G. et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat. Med. 11, 1170\u20131172 (2005).","journal-title":"Nat. Med."},{"key":"BFnrneurol2015248_CR49","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJMoa0803152","volume":"359","author":"RM Gulick","year":"2008","unstructured":"Gulick, R. M. et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 359, 1429\u20131441 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol2015248_CR50","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1126\/science.1241475","volume":"341","author":"Q Tan","year":"2013","unstructured":"Tan, Q. et al. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science 341, 1387\u20131390 (2013).","journal-title":"Science"},{"key":"BFnrneurol2015248_CR51","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.1128\/AAC.49.11.4721-4732.2005","volume":"49","author":"P Dorr","year":"2005","unstructured":"Dorr, P. et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49, 4721\u20134732 (2005).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrneurol2015248_CR52","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1310\/hct1106-351","volume":"11","author":"TJ Wilkin","year":"2010","unstructured":"Wilkin, T. J., Ribaudo, H. R., Tenorio, A. R. & Gulick, R. M. The relationship of CCR5 antagonists to CD4+ T-cell gain: a meta-regression of recent clinical trials in treatment-experienced HIV-infected patients. HIV Clin. Trials 11, 351\u2013358 (2010).","journal-title":"HIV Clin. Trials"},{"key":"BFnrneurol2015248_CR53","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/QAI.0b013e318273015f","volume":"61","author":"L Cuzin","year":"2012","unstructured":"Cuzin, L. et al. Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study. J. Acquir. Immune Defic. Syndr. 61, 557\u2013564 (2012).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"BFnrneurol2015248_CR54","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1097\/QAI.0b013e3181ed18f6","volume":"54","author":"R Rossi","year":"2010","unstructured":"Rossi, R. et al. Downregulation of leukocyte migration after treatment with CCR5 antagonist maraviroc. J. Acquir. Immune Defic. Syndr. 54, e13\u2013e14 (2010).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"BFnrneurol2015248_CR55","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1093\/jac\/dks432","volume":"68","author":"H Arberas","year":"2013","unstructured":"Arberas, H. et al. In vitro effects of the CCR5 inhibitor maraviroc on human T cell function. J. Antimicrob. Chemother. 68, 577\u2013586 (2013).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFnrneurol2015248_CR56","doi-asserted-by":"publisher","first-page":"e13188","DOI":"10.1371\/journal.pone.0013188","volume":"5","author":"N Funderburg","year":"2010","unstructured":"Funderburg, N. et al. Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients. PLoS ONE 5, e13188 (2010).","journal-title":"PLoS ONE"},{"key":"BFnrneurol2015248_CR57","doi-asserted-by":"publisher","first-page":"5858","DOI":"10.1128\/AAC.01406-12","volume":"56","author":"MC Romero-S\u00e1nchez","year":"2012","unstructured":"Romero-S\u00e1nchez, M. C. et al. Effect of maraviroc on HIV disease progression-related biomarkers. Antimicrob. Agents Chemother. 56, 5858\u20135864 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrneurol2015248_CR58","doi-asserted-by":"publisher","first-page":"e27864","DOI":"10.1371\/journal.pone.0027864","volume":"6","author":"C Guti\u00e9rrez","year":"2011","unstructured":"Guti\u00e9rrez, C. et al. Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected. PLoS ONE 6, e27864 (2011).","journal-title":"PLoS ONE"},{"key":"BFnrneurol2015248_CR59","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1093\/infdis\/jiu180","volume":"210","author":"MM Pozo-Balado","year":"2014","unstructured":"Pozo-Balado, M. M. et al. Maraviroc reduces the regulatory T-cell frequency in antiretroviral-naive HIV-infected subjects. J. Infect. Dis. 210, 890\u2013898 (2014).","journal-title":"J. Infect. Dis."},{"key":"BFnrneurol2015248_CR60","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1473-3099(13)70269-X","volume":"13","author":"DB Clifford","year":"2013","unstructured":"Clifford, D. B. & Ances, B. M. HIV-associated neurocognitive disorder. Lancet Infect. Dis. 13, 976\u2013986 (2013).","journal-title":"Lancet Infect. Dis."},{"key":"BFnrneurol2015248_CR61","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1086\/650538","volume":"50","author":"A Canestri","year":"2010","unstructured":"Canestri, A. et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin. Infect. Dis. 50, 773\u2013778 (2010).","journal-title":"Clin. Infect. Dis."},{"key":"BFnrneurol2015248_CR62","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/archneurol.2007.31","volume":"65","author":"S Letendre","year":"2008","unstructured":"Letendre, S. et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch. Neurol. 65, 65\u201370 (2008).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol2015248_CR63","first-page":"137","volume":"19","author":"S Letendre","year":"2011","unstructured":"Letendre, S. Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top. Antivir. Med. 19, 137\u2013142 (2011).","journal-title":"Top. Antivir. Med."},{"key":"BFnrneurol2015248_CR64","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/1471-2377-11-148","volume":"11","author":"LA Cysique","year":"2011","unstructured":"Cysique, L. A., Waters, E. K. & Brew, B. J. Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research. BMC Neurol. 11, 148 (2011).","journal-title":"BMC Neurol."},{"key":"BFnrneurol2015248_CR65","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1097\/QAD.0000000000000096","volume":"28","author":"M Vassallo","year":"2014","unstructured":"Vassallo, M. et al. Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders? AIDS 28, 493\u2013501 (2014).","journal-title":"AIDS"},{"key":"BFnrneurol2015248_CR66","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1093\/cid\/cit921","volume":"58","author":"RJ Ellis","year":"2014","unstructured":"Ellis, R. J. et al. Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder. Clin. Infect. Dis. 58, 1015\u20131022 (2014).","journal-title":"Clin. Infect. Dis."},{"key":"BFnrneurol2015248_CR67","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/QAI.0b013e318274e2b0","volume":"62","author":"A Cusini","year":"2013","unstructured":"Cusini, A. et al. Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. J. Acquir. Immune Defic. Syndr. 62, 28\u201335 (2013).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"BFnrneurol2015248_CR68","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3851\/IMP2560","volume":"18","author":"N Ciccarelli","year":"2013","unstructured":"Ciccarelli, N. et al. Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia. Antivir. Ther. 18, 153\u2013160 (2013).","journal-title":"Antivir. Ther."},{"key":"BFnrneurol2015248_CR69","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1080\/00498250802447409","volume":"38","author":"DK Walker","year":"2008","unstructured":"Walker, D. K. et al. Preclinical assessment of the distribution of maraviroc to potential human immunodeficiency virus (HIV) sanctuary sites in the central nervous system (CNS) and gut-associated lymphoid tissue (GALT). Xenobiotica 38, 1330\u20131339 (2008).","journal-title":"Xenobiotica"},{"key":"BFnrneurol2015248_CR70","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1097\/QAD.0b013e328333ae0e","volume":"23","author":"A Yilmaz","year":"2009","unstructured":"Yilmaz, A., Watson, V., Else, L. & Gissl\u00e8n, M. Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients. AIDS 23, 2537\u20132540 (2009).","journal-title":"AIDS"},{"key":"BFnrneurol2015248_CR71","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1097\/QAI.0b013e3181ef70fe","volume":"55","author":"JM Tiraboschi","year":"2010","unstructured":"Tiraboschi, J. M., Niubo, J., Curto, J. & Podzamczer, D. Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients. J. Acquir. Immune Defic. Syndr. 55, 606\u2013609 (2010).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"BFnrneurol2015248_CR72","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1097\/QAD.0b013e328351f627","volume":"26","author":"D Croteau","year":"2012","unstructured":"Croteau, D. et al. Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50% inhibitory concentration. AIDS 26, 890\u2013893 (2012).","journal-title":"AIDS"},{"key":"BFnrneurol2015248_CR73","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/jac\/dkr427","volume":"67","author":"L Garvey","year":"2012","unstructured":"Garvey, L. et al. CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study. J. Antimicrob. Chemother. 67, 206\u2013212 (2012).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFnrneurol2015248_CR74","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1097\/QAD.0b013e32833c9353","volume":"24","author":"G Melica","year":"2010","unstructured":"Melica, G. et al. Maraviroc-containing regimen suppresses HIV replication in the cerebrospinal fluid of patients with neurological symptoms. AIDS 24, 2130\u20132133 (2010).","journal-title":"AIDS"},{"key":"BFnrneurol2015248_CR75","doi-asserted-by":"publisher","first-page":"F21","DOI":"10.1097\/QAD.0000000000000074","volume":"27","author":"KM Kelly","year":"2013","unstructured":"Kelly, K. M. et al. Neuroprotective maraviroc monotherapy in simian immunodeficiency virus-infected macaques: reduced replicating and latent SIV in the brain. AIDS 27, F21\u2013F28 (2013).","journal-title":"AIDS"},{"key":"BFnrneurol2015248_CR76","first-page":"2767","volume":"37","author":"DJ Roberts","year":"2009","unstructured":"Roberts, D. J. et al. Effect of acute inflammatory brain injury on accumulation of morphine and morphine 3- and 6-glucuronide in the human brain. Crit. Care Med. 37, 2767\u20132774 (2009).","journal-title":"Crit. Care Med."},{"key":"BFnrneurol2015248_CR77","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1056\/NEJMoa1201248","volume":"367","author":"R Reshef","year":"2012","unstructured":"Reshef, R. et al. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N. Engl. J. Med. 367, 135\u2013145 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol2015248_CR78","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1172\/JCI6642","volume":"104","author":"M Murai","year":"1999","unstructured":"Murai, M. et al. Active participation of CCR5+CD8+ T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease. J. Clin. Invest. 104, 49\u201357 (1999).","journal-title":"J. Clin. Invest."},{"key":"BFnrneurol2015248_CR79","doi-asserted-by":"publisher","first-page":"R11","DOI":"10.1186\/ar3685","volume":"14","author":"DL Fleishaker","year":"2012","unstructured":"Fleishaker, D. L. et al. Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial. Arthritis Res. Ther. 14, R11 (2012).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrneurol2015248_CR80","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jaut.2014.06.004","volume":"54","author":"A Ben-Nun","year":"2014","unstructured":"Ben-Nun, A. et al. From classic to spontaneous and humanized models of multiple sclerosis: impact on understanding pathogenesis and drug development. J. Autoimmun. 54, 33\u201350 (2014).","journal-title":"J. Autoimmun."},{"key":"BFnrneurol2015248_CR81","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.4049\/jimmunol.1202026","volume":"189","author":"W Sato","year":"2012","unstructured":"Sato, W. et al. CCR2+CCR5+ T cells produce matrix metalloproteinase-9 and osteopontin in the pathogenesis of multiple sclerosis. J. Immunol. 189, 5057\u20135065 (2012).","journal-title":"J. Immunol."},{"key":"BFnrneurol2015248_CR82","doi-asserted-by":"publisher","first-page":"6873","DOI":"10.1073\/pnas.96.12.6873","volume":"96","author":"KE Balashov","year":"1999","unstructured":"Balashov, K. E., Rottman, J. B., Weiner, H. L. & Hancock, W. W. CCR5+ and CXCR3+ T cells are increased in multiple sclerosis and their ligands MIP-1\u03b1 and IP-10 are expressed in demyelinating brain lesions. Proc. Natl Acad. Sci. USA 96, 6873\u20136878 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2015248_CR83","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1172\/JCI5150","volume":"103","author":"TL S\u00f8rensen","year":"1999","unstructured":"S\u00f8rensen, T. L. et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J. Clin. Invest. 103, 807\u2013815 (1999).","journal-title":"J. Clin. Invest."},{"key":"BFnrneurol2015248_CR84","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1111\/j.1476-5381.2009.00528.x","volume":"158","author":"J Ni","year":"2009","unstructured":"Ni, J. et al. The chemokine receptor antagonist, TAK-779, decreased experimental autoimmune encephalomyelitis by reducing inflammatory cell migration into the central nervous system, without affecting T cell function. Br. J. Pharmacol. 158, 2046\u20132056 (2009).","journal-title":"Br. J. Pharmacol."},{"key":"BFnrneurol2015248_CR85","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/S0002-9440(10)63017-9","volume":"159","author":"C Trebst","year":"2001","unstructured":"Trebst, C. et al. CCR1+\/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. Am. J. Pathol. 159, 1701\u20131710 (2001).","journal-title":"Am. J. Pathol."},{"key":"BFnrneurol2015248_CR86","first-page":"617","volume":"150","author":"AR Glabinski","year":"1997","unstructured":"Glabinski, A. R., Tani, M., Strieter, R. M., Tuohy, V. K. & Ransohoff, R. M. Synchronous synthesis of \u03b1- and \u03b2-chemokines by cells of diverse lineage in the central nervous system of mice with relapses of chronic experimental autoimmune encephalomyelitis. Am. J. Pathol. 150, 617\u2013630 (1997).","journal-title":"Am. J. Pathol."},{"key":"BFnrneurol2015248_CR87","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0165-5728(97)00040-4","volume":"77","author":"R Miyagishi","year":"1997","unstructured":"Miyagishi, R., Kikuchi, S., Takayama, C., Inoue, Y. & Tashiro, K. Identification of cell types producing RANTES, MIP-1\u03b1 and MIP-1\u03b2 in rat experimental autoimmune encephalomyelitis by in situ hybridization. J. Neuroimmunol. 77, 17\u201326 (1997).","journal-title":"J. Neuroimmunol."},{"key":"BFnrneurol2015248_CR88","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/S0165-5728(97)00208-7","volume":"84","author":"JE Simpson","year":"1998","unstructured":"Simpson, J. E., Newcombe, J., Cuzner, M. L. & Woodroofe, M. N. Expression of monocyte chemoattractant protein-1 and other \u03b2-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J. Neuroimmunol. 84, 238\u2013249 (1998).","journal-title":"J. Neuroimmunol."},{"key":"BFnrneurol2015248_CR89","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1046\/j.1365-2249.2000.01334.x","volume":"122","author":"LA Boven","year":"2000","unstructured":"Boven, L. A., Montagne, L., Nottet, H. S. & De Groot, C. J. Macrophage inflammatory protein-1\u03b1 (MIP-1\u03b1), MIP-1\u03b2, and RANTES mRNA semiquantification and protein expression in active demyelinating multiple sclerosis (MS) lesions. Clin. Exp. Immunol. 122, 257\u2013263 (2000).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnrneurol2015248_CR90","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s00011-011-0331-8","volume":"60","author":"HM Zheng","year":"2011","unstructured":"Zheng, H. M., Jiang, Y., Wang, J. R., Gong, X. L. & Guo, B. Y. Mimic peptides bonding specifically with the first and second extracellular loops of the CC chemokine receptor 5 derived from a phage display peptide library are potent inhibitors of experimental autoimmune encephalomyelitis. Inflamm. Res. 60, 759\u2013767 (2011).","journal-title":"Inflamm. Res."},{"key":"BFnrneurol2015248_CR91","doi-asserted-by":"publisher","first-page":"4018","DOI":"10.4049\/jimmunol.172.7.4018","volume":"172","author":"WG Glass","year":"2004","unstructured":"Glass, W. G. et al. Antibody targeting of the CC chemokine ligand 5 results in diminished leukocyte infiltration into the central nervous system and reduced neurologic disease in a viral model of multiple sclerosis. J. Immunol. 172, 4018\u20134025 (2004).","journal-title":"J. Immunol."},{"key":"BFnrneurol2015248_CR92","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/S0165-5728(98)00187-8","volume":"92","author":"KJ Kennedy","year":"1998","unstructured":"Kennedy, K. J., Strieter, R. M., Kunkel, S. L., Lukacs, N. W. & Karpus, W. J. Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-1\u03b1 and monocyte chemotactic protein-1. J. Neuroimmunol. 92, 98\u2013108 (1998).","journal-title":"J. Neuroimmunol."},{"key":"BFnrneurol2015248_CR93","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.4049\/jimmunol.161.8.3870","volume":"161","author":"S Youssef","year":"1998","unstructured":"Youssef, S. et al. Long-lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding C-C chemokines. J. Immunol. 161, 3870\u20133879 (1998).","journal-title":"J. Immunol."},{"key":"BFnrneurol2015248_CR94","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.4049\/jimmunol.155.10.5003","volume":"155","author":"WJ Karpus","year":"1995","unstructured":"Karpus, W. J. et al. An important role for the chemokine macrophage inflammatory protein-1\u03b1 in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J. Immunol. 155, 5003\u20135010 (1995).","journal-title":"J. Immunol."},{"key":"BFnrneurol2015248_CR95","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.4049\/jimmunol.1000666","volume":"185","author":"Y Sapir","year":"2010","unstructured":"Sapir, Y. et al. A fusion protein encoding the second extracellular domain of CCR5 arrests chemokine-induced cosignaling and effectively suppresses ongoing experimental autoimmune encephalomyelitis. J. Immunol. 185, 2589\u20132599 (2010).","journal-title":"J. Immunol."},{"key":"BFnrneurol2015248_CR96","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1002\/(SICI)1521-4141(200005)30:5<1410::AID-IMMU1410>3.0.CO;2-L","volume":"30","author":"EH Tran","year":"2000","unstructured":"Tran, E. H., Kuziel, W. A. & Owens, T. Induction of experimental autoimmune encephalomyelitis in C57BL\/6 mice deficient in either the chemokine macrophage inflammatory protein-1\u03b1 or its CCR5 receptor. Eur. J. Immunol. 30, 1410\u20131415 (2000).","journal-title":"Eur. J. Immunol."},{"key":"BFnrneurol2015248_CR97","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jneuroim.2005.07.025","volume":"169","author":"OH Kantarci","year":"2005","unstructured":"Kantarci, O. H. et al. CCR5\u039432 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis. J. Neuroimmunol. 169, 137\u2013143 (2005).","journal-title":"J. Neuroimmunol."},{"key":"BFnrneurol2015248_CR98","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1191\/1352458504ms994oa","volume":"10","author":"JA Silversides","year":"2004","unstructured":"Silversides, J. A., Heggarty, S. V., McDonnell, G. V., Hawkins, S. A. & Graham, C. A. Influence of CCR5 \u03b432 polymorphism on multiple sclerosis susceptibility and disease course. Mult. Scler. 10, 149\u2013152 (2004).","journal-title":"Mult. Scler."},{"key":"BFnrneurol2015248_CR99","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/S0165-5728(99)00166-6","volume":"102","author":"F Sellebjerg","year":"2000","unstructured":"Sellebjerg, F., Madsen, H. O., Jensen, C. V., Jensen, J. & Garred, P. CCR5 \u039432, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J. Neuroimmunol. 102, 98\u2013106 (2000).","journal-title":"J. Neuroimmunol."},{"key":"BFnrneurol2015248_CR100","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jneuroim.2007.08.005","volume":"190","author":"T van Veen","year":"2007","unstructured":"van Veen, T. et al. CCL5 and CCR5 genotypes modify clinical, radiological and pathological features of multiple sclerosis. J. Neuroimmunol. 190, 157\u2013164 (2007).","journal-title":"J. Neuroimmunol."},{"key":"BFnrneurol2015248_CR101","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ane.12145","volume":"129","author":"M M\u00f8ller","year":"2014","unstructured":"M\u00f8ller, M. et al. The chemokine receptor CCR5 \u039432 allele in natalizumab-treated multiple sclerosis. Acta Neurol. Scand. 129, 27\u201331 (2014).","journal-title":"Acta Neurol. Scand."},{"key":"BFnrneurol2015248_CR102","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S1474-4422(13)70260-6","volume":"13","author":"S Varadkar","year":"2014","unstructured":"Varadkar, S. et al. Rasmussen's encephalitis: clinical features, pathobiology, and treatment advances. Lancet Neurol. 13, 195\u2013205 (2014).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol2015248_CR103","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/ana.10100","volume":"51","author":"CG Bien","year":"2002","unstructured":"Bien, C. G. et al. Destruction of neurons by cytotoxic T cells: a new pathogenic mechanism in Rasmussen's encephalitis. Ann. Neurol. 51, 311\u2013318 (2002).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2015248_CR104","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/ana.21148","volume":"62","author":"J Bauer","year":"2007","unstructured":"Bauer, J. et al. Astrocytes are a specific immunological target in Rasmussen's encephalitis. Ann. Neurol. 62, 67\u201380 (2007).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2015248_CR105","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1093\/brain\/awp003","volume":"132","author":"N Schwab","year":"2009","unstructured":"Schwab, N. et al. CD8+ T-cell clones dominate brain infiltrates in Rasmussen encephalitis and persist in the periphery. Brain 132, 1236\u20131246 (2009).","journal-title":"Brain"},{"key":"BFnrneurol2015248_CR106","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1212\/01.WNL.0000090107.04681.5B","volume":"61","author":"EH Kossoff","year":"2003","unstructured":"Kossoff, E. H. et al. Hemispherectomy for intractable unihemispheric epilepsy etiology versus outcome. Neurology 61, 887\u2013890 (2003).","journal-title":"Neurology"},{"key":"BFnrneurol2015248_CR107","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/epi.12042","volume":"54","author":"CG Bien","year":"2013","unstructured":"Bien, C. G. et al. Rasmussen encephalitis: incidence and course under randomized therapy with tacrolimus or intravenous immunoglobulins. Epilepsia 54, 543\u2013550 (2013).","journal-title":"Epilepsia"},{"key":"BFnrneurol2015248_CR108","doi-asserted-by":"publisher","first-page":"e60","DOI":"10.1016\/S2352-3018(14)70027-X","volume":"1","author":"JG Sierra-Madero","year":"2014","unstructured":"Sierra-Madero, J. G. et al. Effect of the CCR5 antagonist maraviroc on the occurrence of immune reconstitution inflammatory syndrome in HIV (CADIRIS): a double-blind, randomised, placebo-controlled trial. Lancet HIV 1, e60\u2013e67 (2014).","journal-title":"Lancet HIV"},{"key":"BFnrneurol2015248_CR109","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1097\/QAD.0b013e32833365f4","volume":"23","author":"G Martin-Blondel","year":"2009","unstructured":"Martin-Blondel, G. et al. Is maraviroc beneficial in paradoxical progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome management? AIDS 23, 2545\u20132546 (2009).","journal-title":"AIDS"},{"key":"BFnrneurol2015248_CR110","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1093\/brain\/awq365","volume":"134","author":"G Martin-Blondel","year":"2011","unstructured":"Martin-Blondel, G. et al. Pathogenesis of the immune reconstitution inflammatory syndrome affecting the central nervous system in patients infected with HIV. Brain 134, 928\u2013946 (2011).","journal-title":"Brain"},{"key":"BFnrneurol2015248_CR111","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1056\/NEJMc1304828","volume":"370","author":"PS Giacomini","year":"2014","unstructured":"Giacomini, P. S. et al. Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome. N. Engl. J. Med. 370, 486\u2013488 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol2015248_CR112","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00401-015-1383-6","volume":"129","author":"G Martin-Blondel","year":"2015","unstructured":"Martin-Blondel, G. et al. Therapeutic use of CCR5 antagonists is supported by strong expression of CCR5 on CD8+ T cells in progressive multifocal leukoencephalopathy-associated immune reconstitution inflammatory syndrome. Acta Neuropathol. 129, 463\u2013465 (2015).","journal-title":"Acta Neuropathol."},{"key":"BFnrneurol2015248_CR113","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1212\/WNL.0b013e31822e55e7","volume":"77","author":"IL Tan","year":"2011","unstructured":"Tan, I. L., McArthur, J. C., Clifford, D. B., Major, E. O. & Nath, A. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 77, 1061\u20131067 (2011).","journal-title":"Neurology"},{"key":"BFnrneurol2015248_CR114","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1212\/WNL.0b013e31821a446b","volume":"76","author":"P Vermersch","year":"2011","unstructured":"Vermersch, P. et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 76, 1697\u20131704 (2011).","journal-title":"Neurology"},{"key":"BFnrneurol2015248_CR115","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00401-015-1391-6","volume":"129","author":"L Stork","year":"2015","unstructured":"Stork, L., Br\u00fcck, W., Bar-Or, A. & Metz, I. High CCR5 expression in natalizumab-associated progressive multifocal leukoencephalopathy immune reconstitution inflammatory syndrome supports treatment with the CCR5 inhibitor maraviroc. Acta Neuropathol. 129, 467\u2013468 (2015).","journal-title":"Acta Neuropathol."},{"key":"BFnrneurol2015248_CR116","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1084\/jem.20042530","volume":"202","author":"WG Glass","year":"2005","unstructured":"Glass, W. G. et al. Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J. Exp. Med. 202, 1087\u20131098 (2005).","journal-title":"J. Exp. Med."},{"key":"BFnrneurol2015248_CR117","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.4049\/jimmunol.163.9.4642","volume":"163","author":"GB Huffnagle","year":"1999","unstructured":"Huffnagle, G. B. et al. Cutting edge: role of C-C chemokine receptor 5 in organ-specific and innate immunity to Cryptococcus neoformans. J. Immunol. 163, 4642\u20134646 (1999).","journal-title":"J. Immunol."},{"key":"BFnrneurol2015248_CR118","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1371\/journal.ppat.0020049","volume":"2","author":"IA Khan","year":"2006","unstructured":"Khan, I. A. et al. CCR5 is essential for NK cell trafficking and host survival following Toxoplasma gondii infection. PLoS Pathog. 2, e49 (2006).","journal-title":"PLoS Pathog."},{"key":"BFnrneurol2015248_CR119","doi-asserted-by":"publisher","first-page":"e44834","DOI":"10.1371\/journal.pone.0044834","volume":"7","author":"M Larena","year":"2012","unstructured":"Larena, M., Regner, M. & Lobigs, M. The chemokine receptor CCR5, a therapeutic target for HIV\/AIDS antagonists, is critical for recovery in a mouse model of Japanese encephalitis. PLoS ONE 7, e44834 (2012).","journal-title":"PLoS ONE"},{"key":"BFnrneurol2015248_CR120","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1084\/jem.20051970","volume":"203","author":"WG Glass","year":"2006","unstructured":"Glass, W. G. et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J. Exp. Med. 203, 35\u201340 (2006).","journal-title":"J. Exp. Med."},{"key":"BFnrneurol2015248_CR121","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1086\/524691","volume":"197","author":"JK Lim","year":"2008","unstructured":"Lim, J. K. et al. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. J. Infect. Dis. 197, 262\u2013265 (2008).","journal-title":"J. Infect. Dis."},{"key":"BFnrneurol2015248_CR122","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1086\/649426","volume":"201","author":"JK Lim","year":"2010","unstructured":"Lim, J. K. et al. CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission. J. Infect. Dis. 201, 178\u2013185 (2010).","journal-title":"J. Infect. Dis."},{"key":"BFnrneurol2015248_CR123","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1086\/524709","volume":"197","author":"E Kindberg","year":"2008","unstructured":"Kindberg, E. et al. A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis. J. Infect. Dis. 197, 266\u2013269 (2008).","journal-title":"J. Infect. Dis."},{"key":"BFnrneurol2015248_CR124","doi-asserted-by":"publisher","first-page":"e106798","DOI":"10.1371\/journal.pone.0106798","volume":"9","author":"A Mickien\u0117","year":"2014","unstructured":"Mickien\u0117, A. et al. Polymorphisms in chemokine receptor 5 and Toll-like receptor 3 genes are risk factors for clinical tick-borne encephalitis in the Lithuanian population. PLoS ONE 9, e106798 (2014).","journal-title":"PLoS ONE"},{"key":"BFnrneurol2015248_CR125","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.antiviral.2013.05.008","volume":"99","author":"AV Barkhash","year":"2013","unstructured":"Barkhash, A. V., Voevoda, M. I. & Romaschenko, A. G. Association of single nucleotide polymorphism rs3775291 in the coding region of the TLR3 gene with predisposition to tick-borne encephalitis in a Russian population. Antiviral Res. 99, 136\u2013138 (2013).","journal-title":"Antiviral Res."},{"key":"BFnrneurol2015248_CR126","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1086\/590187","volume":"198","author":"B Pulendran","year":"2008","unstructured":"Pulendran, B. et al. Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J. Infect. Dis. 198, 500\u2013507 (2008).","journal-title":"J. Infect. Dis."},{"key":"BFnrneurol2015248_CR127","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1182\/blood.V99.4.1237","volume":"99","author":"A Nansen","year":"2002","unstructured":"Nansen, A. et al. The role of CC chemokine receptor 5 in antiviral immunity. Blood 99, 1237\u20131245 (2002).","journal-title":"Blood"},{"key":"BFnrneurol2015248_CR128","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1128\/IAI.72.2.1057-1064.2004","volume":"72","author":"MX Zhong","year":"2004","unstructured":"Zhong, M. X., Kuziel, W. A., Pamer, E. G. & Serbina, N. V. Chemokine receptor 5 is dispensable for innate and adaptive immune responses to Listeria monocytogenes infection. Infect. Immun. 72, 1057\u20131064 (2004).","journal-title":"Infect. Immun."},{"key":"BFnrneurol2015248_CR129","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jneuroim.2006.12.013","volume":"184","author":"AA Silva","year":"2007","unstructured":"Silva, A. A. et al. Trypanosoma cruzi-triggered meningoencephalitis is a CCR1\/CCR5-independent inflammatory process. J. Neuroimmunol. 184, 156\u2013163 (2007).","journal-title":"J. Neuroimmunol."},{"key":"BFnrneurol2015248_CR130","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1179\/000349804225003271","volume":"98","author":"BY Sarfo","year":"2004","unstructured":"Sarfo, B. Y. et al. The cerebral-malaria-associated expression of RANTES, CCR3 and CCR5 in post-mortem tissue samples. Ann. Trop. Med. Parasitol. 98, 297\u2013303 (2004).","journal-title":"Ann. Trop. Med. Parasitol."},{"key":"BFnrneurol2015248_CR131","doi-asserted-by":"publisher","first-page":"4253","DOI":"10.1182\/blood-2002-05-1493","volume":"101","author":"E Belnoue","year":"2003","unstructured":"Belnoue, E. et al. CCR5 deficiency decreases susceptibility to experimental cerebral malaria. Blood 101, 4253\u20134259 (2003).","journal-title":"Blood"},{"key":"BFnrneurol2015248_CR132","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/S0002-9440(10)65013-4","volume":"156","author":"CM McManus","year":"2000","unstructured":"McManus, C. M. et al. Chemokine and chemokine-receptor expression in human glial elements: induction by the HIV protein, Tat, and chemokine autoregulation. Am. J. Pathol. 156, 1441\u20131453 (2000).","journal-title":"Am. J. Pathol."},{"key":"BFnrneurol2015248_CR133","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1128\/JVI.73.1.205-213.1999","volume":"73","author":"AV Albright","year":"1999","unstructured":"Albright, A. V. et al. Microglia express CCR5, CXCR4, and CCR3, but of these, CCR5 is the principal coreceptor for human immunodeficiency virus type 1 dementia isolates. J. Virol. 73, 205\u2013213 (1999).","journal-title":"J. Virol."},{"key":"BFnrneurol2015248_CR134","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1086\/428095","volume":"191","author":"SS Spudich","year":"2005","unstructured":"Spudich, S. S. et al. HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia. J. Infect. Dis. 191, 890\u2013898 (2005).","journal-title":"J. Infect. Dis."},{"key":"BFnrneurol2015248_CR135","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1086\/421244","volume":"189","author":"BL Shacklett","year":"2004","unstructured":"Shacklett, B. L. et al. Increased adhesion molecule and chemokine receptor expression on CD8+ T cells trafficking to cerebrospinal fluid in HIV-1 infection. J. Infect. Dis. 189, 2202\u20132212 (2004).","journal-title":"J. Infect. Dis."},{"key":"BFnrneurol2015248_CR136","doi-asserted-by":"publisher","first-page":"e28499","DOI":"10.1371\/journal.pone.0028499","volume":"6","author":"P Gramegna","year":"2011","unstructured":"Gramegna, P. et al. In vitro downregulation of matrix metalloproteinase-9 in rat glial cells by CCR5 antagonist maraviroc: therapeutic implication for HIV brain infection. PLoS ONE 6, e28499 (2011).","journal-title":"PLoS ONE"},{"key":"BFnrneurol2015248_CR137","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.4049\/jimmunol.1302915","volume":"193","author":"R Maung","year":"2014","unstructured":"Maung, R. et al. CCR5 knockout prevents neuronal injury and behavioral impairment induced in a transgenic mouse model by a CXCR4-using HIV-1 glycoprotein 120. J. Immunol. 193, 1895\u20131910 (2014).","journal-title":"J. Immunol."},{"key":"BFnrneurol2015248_CR138","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/hiv.12243","volume":"16","author":"J Tiraboschi","year":"2015","unstructured":"Tiraboschi, J. et al. Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch. HIV Med. 16, 388\u2013392 (2015).","journal-title":"HIV Med."},{"key":"BFnrneurol2015248_CR139","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s13365-014-0279-x","volume":"20","author":"LC Ndhlovu","year":"2014","unstructured":"Ndhlovu, L. C. et al. Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND). J. Neurovirol. 20, 571\u2013582 (2014).","journal-title":"J. Neurovirol."},{"key":"BFnrneurol2015248_CR140","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00401-001-0498-0","volume":"103","author":"F Bernal","year":"2002","unstructured":"Bernal, F. et al. Immunohistochemical analysis of anti-Hu-associated paraneoplastic encephalomyelitis. Acta Neuropathol. 103, 509\u2013515 (2002).","journal-title":"Acta Neuropathol."},{"key":"BFnrneurol2015248_CR141","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1093\/brain\/aws082","volume":"135","author":"CG Bien","year":"2012","unstructured":"Bien, C. G. et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain 135, 1622\u20131638 (2012).","journal-title":"Brain"},{"key":"BFnrneurol2015248_CR142","doi-asserted-by":"publisher","first-page":"e27384","DOI":"10.4161\/onci.27384","volume":"2","author":"BS Pignolet","year":"2013","unstructured":"Pignolet, B. S., Gebauer, C. M. & Liblau, R. S. Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies: a beneficial antitumor immune response going awry. Oncoimmunology 2, e27384 (2013).","journal-title":"Oncoimmunology"},{"key":"BFnrneurol2015248_CR143","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/j.intimp.2007.07.019","volume":"7","author":"Y Saita","year":"2007","unstructured":"Saita, Y., Kondo, M. & Shimizu, Y. Species selectivity of small-molecular antagonists for the CCR5 chemokine receptor. Int. Immunopharmacol. 7, 1528\u20131534 (2007).","journal-title":"Int. Immunopharmacol."},{"key":"BFnrneurol2015248_CR144","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.pneurobio.2010.12.003","volume":"93","author":"S Sorce","year":"2011","unstructured":"Sorce, S., Myburgh, R. & Krause, K. H. The chemokine receptor CCR5 in the central nervous system. Prog. Neurobiol. 93, 297\u2013311 (2011).","journal-title":"Prog. Neurobiol."},{"key":"BFnrneurol2015248_CR145","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.cellsig.2004.04.007","volume":"16","author":"M Oppermann","year":"2004","unstructured":"Oppermann, M. Chemokine receptor CCR5: insights into structure, function, and regulation. Cell. Signal. 16, 1201\u20131210 (2004).","journal-title":"Cell. Signal."},{"key":"BFnrneurol2015248_CR146","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1146\/annurev-pathol-020712-164018","volume":"8","author":"S Gheuens","year":"2013","unstructured":"Gheuens, S., W\u00fcthrich, C. & Koralnik, I. J. Progressive multifocal leukoencephalopathy: why gray and white matter. Annu. Rev. Pathol. 8, 189\u2013215 (2013).","journal-title":"Annu. Rev. Pathol."},{"key":"BFnrneurol2015248_CR147","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1473-3099(10)70026-8","volume":"10","author":"M M\u00fcller","year":"2010","unstructured":"M\u00fcller, M. et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect. Dis. 10, 251\u2013261 (2010).","journal-title":"Lancet Infect. Dis."},{"key":"BFnrneurol2015248_CR148","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1212\/WNL.0b013e3182a43e6d","volume":"81","author":"G Martin-Blondel","year":"2013","unstructured":"Martin-Blondel, G. et al. In situ evidence of JC virus control by CD8+ T cells in PML-IRIS during HIV infection. Neurology 81, 964\u2013970 (2013).","journal-title":"Neurology"},{"key":"BFnrneurol2015248_CR149","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00401-011-0900-5","volume":"123","author":"I Metz","year":"2012","unstructured":"Metz, I. et al. Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy. Acta Neuropathol. 123, 235\u2013245 (2012).","journal-title":"Acta Neuropathol."},{"key":"BFnrneurol2015248_CR150","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1212\/01.wnl.0000343510.08643.74","volume":"72","author":"K Tan","year":"2009","unstructured":"Tan, K., Roda, R., Ostrow, L., McArthur, J. & Nath, A. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 72, 1458\u20131464 (2009).","journal-title":"Neurology"},{"key":"BFnrneurol2015248_CR151","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","volume":"9","author":"DB Clifford","year":"2010","unstructured":"Clifford, D. B. et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 9, 438\u2013446 (2010).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol2015248_CR152","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1212\/WNL.0b013e3182768983","volume":"79","author":"C Antoniol","year":"2012","unstructured":"Antoniol, C. et al. Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management? Neurology 79, 2258\u20132264 (2012).","journal-title":"Neurology"}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nrneurol.2015.248.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrneurol.2015.248","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrneurol.2015.248.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T10:48:51Z","timestamp":1692182931000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneurol.2015.248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,18]]},"references-count":152,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["BFnrneurol2015248"],"URL":"https:\/\/doi.org\/10.1038\/nrneurol.2015.248","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726085076.793529615","asserted-by":"object"}]},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,18]]},"assertion":[{"value":"18 January 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}